Thu, Jan. 29, 7:09 AM
- Thermo Fisher Scientific (NYSE:TMO) Q4 results ($M): Total Revenues: 4,492.8 (+29.6%); Life Sciences Solutions: 1,185.2 (+518.3); Analytical Instruments: 902.4 (+1.7%); Specialty Diagnostics: 863.0 (+3.6%); Lab Products & Services: 1,682,9 (+1.8%).
- COGS: 2,290.8 (+18.6%); R&D Expense: 182.5 (+74.3%); SG&A Expense: 1,007.4 (+31.9%); Net Income: 601.2 (+75.7%); EPS: 1.49 (+62.0%); CF Ops: 953.7 (+30.9%); Quick Assets: 1,352.0 (-76.8%).
- Gross Profit: 2,202.0 (+43.4%); COGS: 51.0% (-8.5%); Gross Margin: 49.0% (+10.6%); Operating Earnings: 1,012.1 (+51.7%); Operating Earnings Yield: 22.5% (+17.1%); Net Earnings Yield: 13.4% (+35.6%).
- 2015 Guidance will be provided during the conference call this morning.
Thu, Jan. 29, 6:03 AM| Comment!
Wed, Jan. 21, 1:24 PM
Nov. 25, 2014, 2:46 PM
- "Not surprisingly, billionaires reduced their energy allocations (NYSEARCA:XLE) during Q3," says Direxion, unveiling the quarterly rebalance for the iBillionaire Index (which serves as the benchmark for the IBLN ETF). Attention was instead shifted to healthcare (NYSEARCA:XLV) and materials (NYSEARCA:XLB), with companies like Humana (NYSE:HUM) and Monsanto (NYSE:MON).
- Also added to the index: TMO, GM, FB, CBS, GOOG, MAS, APD, DAL, NOV, WHR, THC, ABBV.
- Dropped from the index: AIG, MCK, CTSH, MSI, RIG, CI, APC, GPS, MSFT, CMCSA, NFLX, MHFI, WMB, ICE.
- Outlying sectors: Consumer Discretionary (NYSEARCA:XLY) makes up 23.33% of the iBillionaire Index vs. 11.68% for the S&P 500, and Industrials (NYSEARCA:XLI) and financials (NYSEARCA:XLF) make up just 6.67% each of the index vs. 10.44 and 16.30 of the S&P 500, respectively. Consumer Staples (NYSEARCA:XLP) have zero representation in the index vs. 9.7% in the S&P 500.
- Previously: Direxion launched an ETF with iBillionaire today
Nov. 7, 2014, 8:42 AM
Oct. 22, 2014, 7:53 AM
- Thermo Fisher (TMO +3.4%) Q3 results: Revenues: $4,171.4M (+30.7%); Life Sciences: $1,071.9M (+541.1%), Analytical Instruments: $786.5M (+2.8%), Specialty Diagostics: $811.8M (+6.9%), Laboratory Products & Services: $1,628.7 (+2.1%); COGS: $2127M (+18.9%); R&D Expense: $175.2M (+82.7%); SG&A: $976.6M (+36.9%); Operating Income: $640.3M (+63.3%); Net Income: $471.6M (+48.5%); EPS: $1.17 (+36.0%); Quick Assets: $534.3M (-89.9%); CF Ops: $1,665.9M (+29.9%).
- 2014 Guidance: Revenues: $16.74B - $16.82B from $16.86B - 16.98B; EPS: $6.87 - $6.95 from $6.85 - $6.97.
Oct. 22, 2014, 6:03 AM| Comment!
Oct. 21, 2014, 5:30 PM
Oct. 1, 2014, 10:18 AM
Sep. 25, 2014, 8:56 AM
- Thermo Fisher Scientific (NYSE:TMO) enters into an agreement with GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) to develop a universal next-generation sequencing (NGS) oncology test for solid tumors that will serve as a companion diagnostic for multiple drug programs.
- The test will be based on Thermo's Ion Personal Genome Machine Dx Platform, Ion AmpliSeq technology and content from the Oncomine Cancer Research Panel. Its value proposition is the ability to analyze hundreds of genes simultaneously thereby enabling clinicians to more fully understand the genetic profile of a tumor. Current genomic analysis technologies interrogate only one or a few genetic markers at a time.
- Financial terms of the collaboration are undisclosed.
Aug. 23, 2014, 7:58 AM
- Joel Greenblatt made investors fortunes at his hedge fund 30 years ago by holding a highly concentrated basket - six to eight names - of deep-value stocks, but his approach today is somewhat different: Buy more than 300 high-quality stocks trading at cheap prices and short more than 300 expensive, lower-quality names. Stocks are weighted in the portfolio depending on where they rank along that spectrum.
- Greenblatt: "[My partner] and I would wake up some days and lose 15% or 20% of our net worth ... now it's more like 15 or 20 basis points."
- The strategy is also available in a trio of mutual funds Greenblatt's Gotham Asset Management offers, and they now account for more than half of Gotham's $7B in AUM.
- A top position last year remaining a large holding after a big run higher is Apple, thanks to "huge returns on capital" and 11% earnings yield. As for Apple's future, Greenblatt will leave that for others to debate: "I don't own just Apple. I own a bucket of companies like Apple, and over time, I know my bucket is going to work."
- Top 5 long holdings now: ENR, SAFM, BG, AXE, CAT.
- Top 5 short holdings now: SUSS, THC, BOBE, KMT, TMO.
Jul. 23, 2014, 6:57 AM
- Thermo Fisher (NYSE:TMO) Q2 Results: Revenues: $4,321.9M (+33.4%), Life Sciences: $1,103.1M (+509%), Analytical Instruments: $793.4M (+43%), Specialty Diagostics: $855.1M (+7.7%), Laboratory Products & Services: $1,699.4 (+6.5%); COGS: $2,361.0M (+29.7%); SG&A Expense: $1,024.6M (+39.5%); R&D Expense: $183.7M (+90.0%); Operating Income: $348.1M (-7.2%); Net Income: $278.5M (0.4%); EPS: $0.69 (-9.2%); Quick Assets: $605.9M (-89.6%); CF Ops (1H): $989.9M (+27.4%).
- 2014 Guidance: Revenues: $16.86B - 16.98B from $16.84B - $17.00B; EPS: $6.85 - 6.97 from $6.80 - 6.95.
Jul. 23, 2014, 6:01 AM| Comment!
Jul. 22, 2014, 5:30 PM
Jul. 10, 2014, 4:35 PM| Comment!
May. 29, 2014, 2:06 PM| Comment!
TMO vs. ETF Alternatives
Thermo Fisher Scientific Inc offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs.
Other News & PR